OraSure Technologies (NASDAQ:OSUR) Stock Rating Lowered by StockNews.com

OraSure Technologies (NASDAQ:OSUR) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

Separately, Evercore ISI dropped their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, OraSure Technologies presently has an average rating of “Hold” and an average target price of $6.38.

OraSure Technologies Price Performance

OraSure Technologies stock traded up $0.18 during mid-day trading on Tuesday, reaching $5.53. 712,052 shares of the company traded hands, compared to its average volume of 892,587. The firm’s 50 day moving average price is $6.42 and its 200 day moving average price is $6.82. The firm has a market capitalization of $423.10 million, a price-to-earnings ratio of 7.68 and a beta of 0.15. OraSure Technologies has a 52-week low of $4.38 and a 52-week high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.09. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The firm had revenue of $75.88 million for the quarter, compared to analysts’ expectations of $74.13 million. During the same quarter in the previous year, the business posted $0.21 EPS. The company’s quarterly revenue was down 38.3% on a year-over-year basis. On average, sell-side analysts anticipate that OraSure Technologies will post -0.11 EPS for the current year.

Hedge Funds Weigh In On OraSure Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AJOVista LLC purchased a new stake in shares of OraSure Technologies during the 4th quarter valued at about $39,000. Tocqueville Asset Management L.P. purchased a new stake in shares of OraSure Technologies during the 3rd quarter valued at about $75,000. Pathstone Family Office LLC purchased a new stake in shares of OraSure Technologies during the 3rd quarter valued at about $80,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of OraSure Technologies during the 4th quarter valued at about $113,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of OraSure Technologies during the 4th quarter valued at about $115,000. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.